Summary.-The effect of 6 putative prognostic factors on survival was studied in patients with Stages III and IV malignant teratoma of the testis. Differences between survival curves were tested for statistical significance. A diameter > 5 cm in the largest tumour mass, and >8 pulmonary metastases were adverse prognostic factors (P=00004 and 0f008 respectively). Patients with malignant teratoma, trophoblastic, fared worse than those with malignant teratoma, undifferentiated, and malignant teratoma, intermediate (P=00011 and 0-023 respectively). Previous chemotherapy or radiotherapy had no significant effect.
SINCE THE INTRODUCTION of combination chemotherapy for advanced metastatic testicular teratoma in the 1 960s, there has been a progressive improvement in the long-term disease-free survival (MacKenzie, 1966; Jacobs et al., 1979) . Improved chemotherapy regimens including vinblastine and bleomycin (Samuels et al., 1976) and, more recently, cisplatinum (Golbey et al., 1979; Einhorn & Donohue, 1979; Newlands et al., 1980) have produced disease-free survival of more than 2 years in 30-74°O of patients. It would be advantageous to be able to predict which patients are unlikely to achieve full remission with present therapy.
The relationship of tumour bulk to prognosis is widely recognized (Samuels et al., 1976; Einhorn & Donohue, 1977; Peckham et al., 1977) but tumour bulk, as estimated by a variety of methods, is not readily quantified. Studies of putative prognostic factors related to tumour bulk are reported in this paper.
Human chorionic gonadotrophin (hCG) and a-foetoprotein (AFP) are found separately or together in the serum of more than 75% of patients with disseminated malignant teratoma (Newlands et al., 1976; Javadpour, 1979) . Changes in the concentration of these markers in serum are usually related to the bulk of tumour in an individual patient (Javadpour, 1979 disease (Schultz et al., 1978) . Although not all cells in malignant teratomas secrete these markers, it is possible that their serum concentrations can be related to overall tumour bulk and, on the evidence presented here, can provide the most consistent indication of prognosis.
METHODS
Forty-seven patients with malignant teratoma of the testis Stages III (5) and IV (42) (Smithers & Wallace, 1962) (Nie et al., 1977) in which differences in the survival curves were tested for statistical significance by a non-parametric technique described by Lee & Desu (1972 (Fig. 4) ; X2 = 6 45, P = 0 011 for the comparison with malignant teratoma, undifferentiated, and x2 = 5-16, P= 0*023 for the comparison with malignant teratoma, intermediate.
AFP
Fig . 5 shows that AFP > 103 MRC u/ml (1 MRC u/ml =1 ,ug/l) immediately before starting chemotherapy, is associated with a relatively poor prognosis (x2= 6X67, P= 0.010). AFP > 5 x 102 MRC u/ml had no significant effect on survival (x2 = 1 165, P = 0 200) when investigated by the same method (data not shown).
hCG Fig. 6 shows that hCG > 105 miu/ml is associated with a poor prognosis (x2 = 12X18, P=0.001). A significant but less marked difference was also found between hCG above and below 5 x 104 miu/ml (X2= 689,P=0009; data not shown).
Tumour markers in combination
The most consistent indication of prognosis was given by combination of measurements of both tumour markers: patients with neither AFP > 103 MRC u/ml, nor hCG > 105 miu/ml, fared significantly better than those with either or both factors (X2 = 17-79, P = 0O001; Fig. 7 ).
DISCUSSION
The results show that serum concentrations of AFP > 103 MRC u/ml and hCG > 105 miu/ml predict poor survival in patients with malignant teratoma of the testis. A large bulk of tumour at the start of treatment also predicts poor prognosis, but high concentrations of the tumour markers appear to give a more accurate indication of the outcome, producing the highest x2 (17.79) when used in combination. This may be because they reflect the number of tumour cells more accurately than the relatively crude methods for physical assessment of tumour bulk which cannot assess the viable tumour fraction within a mass.
Whilst hCG and AFP are produced by trophoblastic and yolk-sac elements of the (Kuram etal., 1977 al., 1978) . In our view, measurethey may contain a group of tumours ments should also be made monthly for with a different natural history.
at least 5 years after the patients are A number of authors have suggested apparently free from disease by all parathat high concentrations of tumour mar-meters. In this way it will usually be poskers might be associated with poor prog-sible to detect early relapse and re-start nosis (Einhorn & Donohue, 1977; Storer 
